Kyverna Therapeutics granted FDA fast track designation for KYV-101 in the treatment of patients with refractory myasthenia gravis

Kyverna Therapeutics

13 December 2023 - KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven auto-immune diseases.

Kyverna Therapeutics today announced it received fast track designation by the US FDA for its autologous, fully human CD19 chimeric antigen receptor T-cell product candidate, KYV-101, to be used for the treatment of myasthenia gravis.

Read Kyverna Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track